Method of weighted proportion of reproductive-aged women taking folic acid supplements to predict a neural tube defect rate decline

2003 ◽  
Vol 67 (12) ◽  
pp. 959-967 ◽  
Author(s):  
Quanhe Yang ◽  
Michael Atkinson ◽  
J. David Erickson
Keyword(s):  
Folic Acid ◽  
Neural Tube ◽  
Neural Tube Defect ◽  
Defect Rate ◽  
Folic Acid Supplements ◽  
Reproductive Aged Women ◽  
Weighted Proportion

scholarly journals Neural Tube Defects: A case report

2018 ◽  
Vol 14 (4) ◽  
pp. 228-230
Author(s):  
Bishnu Gautam
Keyword(s):  
Folic Acid ◽  
Case Report ◽  
Neural Tube ◽  
Neural Tube Defects ◽  
Neural Tube Defect ◽  
Prenatal Counseling ◽  
Folic Acid Supplement ◽  
Folic Acid Supplements ◽  
Period Of Gestation

Neural tube defect is rare congenital defect of fetus. I have a case of 13 weeks period of gestation with meningomeyelocele came for termination of pregnancy. The diagnosis was confirmed by ultrasonography. History suggests that patient had previous neural tube defect baby, non-compliance to folic acid supplements. It is concluded that prenatal counseling, adherence to folic acid supplement and regular follow-up can prevent further complication.

Folic acid absorption in women with a history of pregnancy with neural tube defect

1995 ◽  
Vol 62 (4) ◽  
pp. 782-784 ◽  
Author(s):  
B A Davis ◽  
L B Bailey ◽  
J F Gregory ◽  
J P Toth ◽  
J Dean ◽  
...  
Keyword(s):  
Folic Acid ◽  
Neural Tube ◽  
Neural Tube Defect ◽  
Acid Absorption ◽  
Folic Acid Absorption ◽  
History Of

scholarly journals Level of Folic Acid and Vitamin B12 in Mothers and Children with Neural Tube Defect

2015 ◽  
Vol 8 (1-3) ◽  
pp. 14-18
Author(s):  
Amalia Tri Utami ◽  
Siti Chandra Windu Baktiyani ◽  
Moch. Istiadjid Eddy Santosa
Keyword(s):  
Folic Acid ◽  
Vitamin B12 ◽  
Neural Tube ◽  
Neural Tube Defect ◽  
Mothers And Children

scholarly journals Weekly iron–folic acid supplements containing 2.8 mg folic acid are associated with a lower risk of neural tube defects than the current practice of 0.4 mg: a randomised controlled trial in Malaysia

2020 ◽  
Vol 5 (12) ◽  
pp. e003897
Author(s):  
Kaitlyn L I Samson ◽  
Su Peng Loh ◽  
Siew Siew Lee ◽  
Dian C Sulistyoningrum ◽  
Geok Lin Khor ◽  
...  
Keyword(s):  
Folic Acid ◽  
Neural Tube ◽  
Controlled Trial ◽  
Clinical Trial Registry ◽  
Double Blind ◽  
Folic Acid Supplements ◽  
Registration Number ◽  
Menstruating Women ◽  
Iron Folic Acid ◽  
Randomised Controlled

IntroductionWeekly iron–folic acid (IFA) supplements are recommended for all menstruating women in countries where anaemia prevalence is >20%. Anaemia caused by folate deficiency is low worldwide, and the need to include folic acid is in question. Including folic acid might reduce the risk of a neural tube defect (NTD) should a woman become pregnant. Most weekly supplements contain 0.4 mg folic acid; however, WHO recommends 2.8 mg because it is seven times the daily dose effective in reducing NTDs. There is a reluctance to switch to supplements containing 2.8 mg of folic acid because of a lack of evidence that this dose would prevent NTDs. Our aim was to investigate the effect of two doses of folic acid, compared with placebo, on red blood cell (RBC) folate, a biomarker of NTD risk.MethodsWe conducted a three-arm double-blind efficacy trial in Malaysia. Non-pregnant women (n=331) were randomised to receive 60 mg iron and either 0, 0.4, or 2.8 mg folic acid once weekly for 16 weeks.ResultsAt 16 weeks, women receiving 0.4 mg and 2.8 mg folic acid per week had a higher mean RBC folate than those receiving 0 mg (mean difference (95% CI) 84 (54 to 113) and 355 (316 to 394) nmol/L, respectively). Women receiving 2.8 mg folic acid had a 271 (234 to 309) nmol/L greater mean RBC folate than those receiving 0.4 mg. Moreover, women in the 2.8 mg group were seven times (RR 7.3, 95% CI 3.9 to 13.7; p<0.0001) more likely to achieve an RBC folate >748 nmol/L, a concentration associated with a low risk of NTD, compared with the 0.4 mg group.ConclusionWeekly IFA supplements containing 2.8 mg folic acid increases RBC folate more than those containing 0.4 mg. Increased availability and access to the 2.8 mg formulation is needed.Trail registration numberThis trial is registered with the Australian New Zealand Clinical Trial Registry (ACTRN12619000818134).

Sign in / Sign up

Export Citation Format

Share Document